Drug intelligence / Profile preview

Yiqing Fang

Development stage: Unknown
Lead developer: Shenzhen Second People’s Hospital
Administration: Oral

Overview

Yiqing Fang is a Traditional Chinese Medicine (TCM) decoction developed for the treatment of uric acid nephropathy and hyperuricemia. It is typically administered via retention enema, often in conjunction with high colon dialysis. The formula is designed to facilitate the excretion of uric acid and other metabolic wastes through the intestinal pathway, thereby reducing the burden on the kidneys and mitigating renal damage associated with chronic kidney disease. It is primarily studied at institutions like Shenzhen Second People's Hospital.

Other names: 益清方

Beyond the preview

Go deeper on Yiqing Fang.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yiqing Fang.

Explore the full profile